MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs.

ABSTRACT: Given the scale and rapid spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, or 2019-nCoV), there is an urgent need to identify therapeutics that are effective against COVID-19 before vaccines are available. Since the current rate of SARS-CoV-2 knowledge acquisition via traditional research methods is not sufficient to match the rapid spread of the virus, novel strategies of drug discovery for SARS-CoV-2 infection are required. Structure-based virtual screening for example relies primarily on docking scores and does not take the importance of key residues into consideration, which may lead to a significantly higher incidence rate of false-positive results. Our novel in silico approach, which overcomes these limitations,

SUBMITTER: Feng Z 

PROVIDER: S-EPMC7665328 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature